Once you know the big pharmaceutical companies are spending a lot of money looking for glucagon receptor antagonists and testing them, and GIP receptor antagonists and testing them, it requires a lot of gusto, a lot of lunacy and craziness to say, nah, I believe all these big pharmaceutical companies are wrong, my lab is doing the opposite. But now, the sentiment has drastically shifted and many companies are looking to co-agonist drugs to achieve over 20%, or even close to 30% weight loss
The consistency across dose groups is telling
BPC-157 consistently upregulates VEGF in preclinical models, building the vascular network that increases oxygen and nutrient delivery to the repair site
So that sector we think continues to have momentum
we want to give you a tool that actually works with your biology
They also mention that tesofensine at 0.5 mg causes twice the weight loss observed with sibutramine and rimonabant